Page results
-
Arif Ahmed is an entrepreneur and private equity investor in healthcare, technology, e-commerce and B2B services companies. He has a proven track record of scaling innovation in complex regulatory environments.
-
UCLH has recruited the first patient to a global study of a new drug in early development, called NI0752, which is thought to reduce the production of a protein in the brain called tau.
-
This information is for patients receiving steroids for immunotherapy toxicity.
-
This page is for patients receiving steroids for immunotherapy toxicity.
-
Researchers at UCLH and UCL have completed the first and only randomised trial to explore a new approach to treating aggressive lung cancer.
-
The world’s first COVID-19 vaccine study researching alternating doses and intervals of approved vaccines is taking place at UCLH.
-
Court of Appeal has ruled in favour of the Tavistock and Portman NHS Trust, which leads the national Gender Identity and Development Service (GIDS).
-
Bladder cancer is where a growth of abnormal tissue, known as a tumour, develops in the bladder lining. In some cases, the tumour spreads into the surrounding areas.
-
A new surgical technique could remove the risk of urinary incontinence after surgery to remove the prostate for men with prostate cancer.
-
A UCLH rheumatology team is leading an exciting project to help understand the reasons for young people missing their hospital appointments and find ways to improve this.
File results
-
FOI/2024/0530 - Radiology/ imaging examinations/ patient access to radiology images
-
FOI/2024/0518 - Post partum balloons buying/ usage numbers
-
FOI/2024/0520 - Treatment of melanoma
-
FOI/2024/05523 - Dabrafenib + Trametinib cancer treatment for metastatic and adjuvant melanoma/ lung/ colorectal cancer
-
FOI/2024/0527 - Treatment for renal cell carcinoma
-
FOI/2024/0528 - Open MRIs referrals for patient size/ spend on specialist bariatric equipment 2017-2024
-
FOI/2024/0529 - Medical Associate Professionals (MAPs) at Trust
-
FOI/2024/0360 - Radiology Information System (RIS) supplier/ contract/ staff details
-
FOI/2024/0357 - Multiple myeloma treatments
-
FOI/2024/0356 - Treatment with Durvalumab and Nivolumab for biliary tract/ non-small cell lung cancer